JP2015528110A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528110A5
JP2015528110A5 JP2015520167A JP2015520167A JP2015528110A5 JP 2015528110 A5 JP2015528110 A5 JP 2015528110A5 JP 2015520167 A JP2015520167 A JP 2015520167A JP 2015520167 A JP2015520167 A JP 2015520167A JP 2015528110 A5 JP2015528110 A5 JP 2015528110A5
Authority
JP
Japan
Prior art keywords
cancer
patient
yeast
class
mass spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520167A
Other languages
English (en)
Japanese (ja)
Other versions
JP6355630B2 (ja
JP2015528110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/032024 external-priority patent/WO2014003853A1/en
Publication of JP2015528110A publication Critical patent/JP2015528110A/ja
Publication of JP2015528110A5 publication Critical patent/JP2015528110A5/ja
Application granted granted Critical
Publication of JP6355630B2 publication Critical patent/JP6355630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520167A 2012-06-26 2013-03-15 質量スペクトルを用いて免疫応答発生治療剤で治療する癌患者を選択または除外する方法 Active JP6355630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664308P 2012-06-26 2012-06-26
US201261664329P 2012-06-26 2012-06-26
US61/664,329 2012-06-26
US61/664,308 2012-06-26
PCT/US2013/032024 WO2014003853A1 (en) 2012-06-26 2013-03-15 Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies

Publications (3)

Publication Number Publication Date
JP2015528110A JP2015528110A (ja) 2015-09-24
JP2015528110A5 true JP2015528110A5 (enExample) 2016-05-12
JP6355630B2 JP6355630B2 (ja) 2018-07-11

Family

ID=48045749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520167A Active JP6355630B2 (ja) 2012-06-26 2013-03-15 質量スペクトルを用いて免疫応答発生治療剤で治療する癌患者を選択または除外する方法

Country Status (13)

Country Link
US (2) US9653272B2 (enExample)
EP (1) EP2864792A1 (enExample)
JP (1) JP6355630B2 (enExample)
KR (1) KR102103319B1 (enExample)
CN (1) CN104685360B (enExample)
AU (1) AU2013281221B2 (enExample)
CA (1) CA2878044C (enExample)
HK (1) HK1209835A1 (enExample)
IL (1) IL236266A0 (enExample)
MX (1) MX365418B (enExample)
SG (1) SG11201408652SA (enExample)
TW (1) TWI639001B (enExample)
WO (1) WO2014003853A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864792A1 (en) 2012-06-26 2015-04-29 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US11594403B1 (en) 2014-12-03 2023-02-28 Biodesix Inc. Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
EP3286213B1 (en) 2015-04-20 2021-08-04 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016175990A1 (en) * 2015-04-30 2016-11-03 Biodesix, Inc. Bagged filtering method for selection and deselection of features for classification
US10974077B2 (en) 2015-06-03 2021-04-13 Montefiore Medical Center Low intensity focused ultrasound for treating cancer and metastasis
CN112710723B (zh) * 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
JP6952056B2 (ja) * 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. 疾患診断を改善するシステム及び方法
WO2017136139A1 (en) * 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
US11232940B2 (en) * 2016-08-02 2022-01-25 Virgin Instruments Corporation Method and apparatus for surgical monitoring using MALDI-TOF mass spectrometry
EP3566054A4 (en) 2017-01-05 2020-12-09 Biodesix, Inc. PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY
EP3631839B1 (en) * 2017-05-22 2024-04-03 Beckman Coulter, Inc. Integrated sample processing system with multiple detection capability
WO2019094802A1 (en) 2017-11-09 2019-05-16 Montefiore Medical Center Low energy immune priming for treating cancer and metastasis
WO2019118873A2 (en) 2017-12-15 2019-06-20 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3773691A4 (en) 2018-03-29 2022-06-15 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
WO2020167471A1 (en) * 2019-02-15 2020-08-20 Biodesix, Inc. Predictive test for identification of early stage nsclc patients at high risk of recurrence after surgery
CN110674947B (zh) * 2019-09-02 2021-02-19 三峡大学 基于Stacking集成框架的光谱特征变量选择与优化方法
EP4046183A1 (en) * 2019-10-17 2022-08-24 DH Technologies Development Pte. Ltd. Threshold-based ida exclusion list
CN112164448B (zh) * 2020-09-25 2021-06-22 上海市胸科医院 免疫治疗疗效预测模型训练方法、预测系统及方法和介质
CN116685259A (zh) * 2020-10-19 2023-09-01 本-古里安大学B.G.内盖夫技术和应用公司 尿细菌对抗生素的敏感性的快速直接鉴定和确定

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
JPS61219387A (ja) * 1985-03-27 1986-09-29 Suntory Ltd 新規な酵母プラスミドおよびその形質転換体
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
EP0721341A4 (en) 1993-08-06 1998-04-22 Cytel Corp CLONING AND DESCRIPTION OF FULL MAGE-1 GENE CHARACTERISTICS
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20070048860A1 (en) 1997-10-10 2007-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Carcinoembryonic antigen (CEA) peptides
US20010055589A1 (en) 1998-06-17 2001-12-27 University Of Connecticut Cancer immunotherapy improved by prior radiotherapy
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ES2260078T3 (es) 2000-04-06 2006-11-01 Seer Pharmaceuticals, Llc. Sistema de administracion microbiana.
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
AU2002252456A1 (en) 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8135136B2 (en) 2004-09-06 2012-03-13 Koninklijke Philips Electronics N.V. Audio signal enhancement
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
US8013927B2 (en) 2005-07-08 2011-09-06 Nikon Corporation Solid-state image sensors
US20100034840A1 (en) 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
MX2008009929A (es) 2006-02-02 2008-10-01 Globeimmune Inc Vacuna a base de levadura para inducir una respuesta inmune.
CN101448848B (zh) 2006-03-27 2013-12-04 全球免疫股份有限公司 Ras突变及其相关组合物和方法
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7858389B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
US8024282B2 (en) 2006-03-31 2011-09-20 Biodesix, Inc. Method for reliable classification of samples in clinical diagnostics using an improved method of classification
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
WO2008085024A1 (en) * 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
EP2134358A1 (en) 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009149714A1 (en) 2008-06-11 2009-12-17 Bruenner Nils Aage Selection of colorectal cancer patients for neo-adjuvant and adjuvant systemic anti-cancer treatment
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
WO2010080804A1 (en) * 2009-01-06 2010-07-15 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
JP2011001315A (ja) 2009-06-19 2011-01-06 Cellex Corp 膵臓癌の免疫療法剤
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
EP2539704A4 (en) 2010-02-24 2015-12-02 Biodesix Inc CANCER PATIENT SELECTION FOR ADMINISTRATION OF THERAPEUTIC AGENTS USING MASS SPECTROMETRY ANALYSIS
JP2013522302A (ja) 2010-03-14 2013-06-13 グローブイミューン，インコーポレイテッド 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP2668504A4 (en) 2011-01-28 2015-06-10 Biodesix Inc PREDICTIVE TEST FOR SELECTING PATIENTS WITH METASTATIC BREAST CANCERS TO RECEIVE HORMONE THERAPY AND POLY THERAPY
AP2013007110A0 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
AU2012228937B2 (en) 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
BR112013032381B1 (pt) 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
RU2017143985A (ru) 2011-08-17 2019-02-14 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
CA2856981A1 (en) 2011-11-23 2013-06-27 Uti Limited Partnership Expression signature for staging and prognosis of prostate, breast and leukemia cancers
JP2015514222A (ja) 2012-04-13 2015-05-18 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム トリプルネガティブ乳癌についてのバイオマーカー
US9279798B2 (en) * 2012-05-29 2016-03-08 Biodesix, Inc. Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof
EP2864792A1 (en) 2012-06-26 2015-04-29 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
CH715107B1 (fr) 2018-06-18 2021-12-30 Montres Breguet Sa Mécanisme de réglage pour mécanisme d'affichage d'horlogerie à rouleau.

Similar Documents

Publication Publication Date Title
JP2015528110A5 (enExample)
Morad et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Li et al. Current clinical progress of PD-1/PD-L1 immunotherapy and potential combination treatment in non–small cell lung cancer
Spina et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Ko et al. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality
Combes et al. Defining and using immune archetypes to classify and treat cancer
Bohannon et al. Identification of dynapenia in older adults through the use of grip strength t‐scores
Scifo et al. Sustained molecular pathology across episodes and remission in major depressive disorder
Xie et al. An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis
HK1209835A1 (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
Sarazin et al. The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer’s disease
Choi et al. Validation of previous spirometric reference equations and new equations
Guo et al. Electroacupuncture pretreatment exhibits anti-depressive effects by regulating hippocampal proteomics in rats with chronic restraint stress
Mismetti et al. Interstitial lung disease associated with systemic sclerosis
Guberina et al. Combined radiation-and immune checkpoint-inhibitor-induced pneumonitis–the challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging
Betancourt et al. The animal cachexia score (ACASCO)
Yang et al. A clinical-information-free method for early diagnosis of lung cancer from the patients with pulmonary nodules based on backpropagation neural network model
WO2018026969A3 (en) Plazomicin antibodies and methods of use
Yang et al. GV‐971 attenuates the progression of neuromyelitis optica in murine models and reverses alterations in gut microbiota and associated peripheral abnormalities
Zattarin et al. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
Moré et al. Feasibility and potential utility of multicomponent exhaled breath analysis for predicting development of radiation pneumonitis after stereotactic ablative radiotherapy
Kang et al. Comparison of Gait variables and Relative Risk of Falls According to Walking Speed During Flat and Obstacles Walking of Fallers and Non-Fallers in Korean Elderly Women
Turcotte et al. Proinflammatory cytokine and adipokine levels in adult unrelated marrow donors are not associated with hematopoietic cell transplantation outcomes
Martinotti et al. Use of novel psychoactive substances and induced psychiatric symptoms: Outcomes from the Eivissa Project